NCT03242915View on ClinicalTrials.gov

Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

February 20, 2025

Study Completion Date

February 20, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Pembrolizumab

200mg IV every 3 weeks

DRUG

Carboplatin

AUC 5 IV every 3 weeks

DRUG

Pemetrexed

500 mg/m\^2 IV every 3 weeks

Trial Locations (7)

10467

Montefiore Cancer Center, The Bronx

37203

Sarah Cannon, Nashville

44195

Cleveland Clinic, Cleveland

48109

The University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

Barbara Ann Karmanos Cancer Institute, Detroit

48202

Henry Ford Cancer Institute/Henry Ford Hospital, Detroit

60612

Rush University Medical Center, Chicago

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER

NCT03242915 - Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents | Biotech Hunter | Biotech Hunter